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Lack of association between hyperglycaemia at arrival
and clinical outcomes in acute stroke patients treated
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Rationale Hyperglycaemia is associated with adverse out-
comes in some studies of acute ischaemic stroke.
Aims We hypothesised that in thrombolytic-treated stroke
patients, hyperglycaemia would be independently associated
with haemorrhagic transformation and unfavourable
outcome.
Design Consecutive rt-PA-treated acute ischaemic stroke pa-
tients presenting to four emergency departments were ana-
lysed. Associations of initial blood glucose and survival to
hospital discharge, symptomatic intracerebral haemorrhage,
any form of intracerebral haemorrhage, and disability at
hospital discharge were determined. Potentially confounding
factors of age, National Institutes of Health Stroke Scale, and
smoking were analysed by univariate logistic regression and
those with Po0.3 included in the multivariate model.
Study Outcome In 268 patients, initial glucose values ranged
from 62 to 507 mg/dl (mean 131). Elevated glucose at arrival
was not significantly associated with any adverse clinical
outcomes. A trend towards higher mortality in hyperglycae-
mic patients (odds ratio 1.71 per 100 mg/dl increase in glu-
cose, 95% confidence interval 0.92–3.13, P 5 0.08) was seen,
but is of unclear significance, and was not corroborated by
effects on discharge disability, symptomatic intracerebral
haemorrhage or intracerebral haemorrhage.
Conclusions Thrombolytic-treated stroke patients with hy-
perglycaemia at presentation did not have significantly worse
outcomes than others in this cohort. These data fail to confirm
previously described associations seen in similarly sized stu-
dies. Further study of these associations and their magnitude
are necessary to better define the relationship between
serum glucose and outcome in thrombolytic-treated acute
ischaemic stroke.
Key words: acute ischaemic stroke, hyperglycaemia, observa-
tional study, outcomes, thrombolysis
Introduction
Hyperglycaemia is common in the acute phase of ischaemic
stroke and has been associated with adverse outcomes, speci-
fically increased risk of haemorrhagic transformation, disabil-
ity, increased health care costs and death in some studies (1, 2).
In some experimental stroke models, hyperglycaemia increases
reperfusion injury and infarct related haemorrhage (3, 4).
It also has been shown to increase infarct volume in some
human and animal studies (5, 6). In studies examining
thrombolysis in ST-segment elevation myocardial infarction,
hyperglycaemia diminishes the resolution of ST-segment
elevation, suggesting hyperglycaemia attenuates the efficacy
of thrombolysis (7). Only a small number of studies have
examined the outcomes and complications of thrombolytic-
treated stroke patients with hyperglycaemia (8–10).
Previous trials of intensive in-hospital control of glucose in
stroke patients have been completed and others are ongoing
(11–13). Recent trials of glucose lowering in stroke and
intensive care have failed to demonstrate improved outcomes
in patients with tight glycaemic control, illustrating the need
for additional observational data on the relationship between
glucose and stroke, especially in thrombolytic-treated patients
(14, 15). The current acute stroke management guideline
recommends treatment of hyperglycaemia and suggests use
of insulin when glucose levels are in excess of 140 mg/dl, but
does not specifically address or advocate glucose lowering
before thrombolysis (16). Thrombolytic treatment guidelines
in existence during the time period examined in this study
recommended withholding tPA therapy when patients have
very high glucose levels (4400 mg/dl) due to concerns of
treating patients with clinical presentations mimicking acute
ischaemic stroke (17).DOI: 10.1111/j.1747-4949.2010.00425.x
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In this analysis, we hypothesised that in rt-PA-treated stroke
patients, hyperglycaemia at presentation would be an inde-
pendent risk factor for cerebral haemorrhage and for unfa-
vourable clinical outcome. We determined the odds ratios
(OR) for poor outcomes related to blood glucose on presenta-
tion in a large cohort of intravenous (IV) rt-PA-treated acute
stroke patients.
Methods
Consecutive stroke patients treated with IV rt-PA between
1 January 1996 and 1 January 2005 were identified from four
emergency departments (EDs) serving a contiguous, four
county region in Michigan. The Institutional Review Board
from each site approved the study before data collection. Four
independent, trained study personnel completed all reviews
using the paper chart and/or electronic medical record.
A standardised data collection form was used. Cases were
identified using four deliberately redundant methods: (1)
discharge diagnoses containing any International Classified
Diseases Version 9 (ICD-9) Code for cerebrovascular disease
(430–437; 99702) plus a procedure code for thrombolysis
(9910 or CPT codes 37195 or 37201); (2) review of hospital
pharmacy logs of rt-PA use in ED; (3) review of site-specific
stroke registries maintained for quality improvement purposes
and (4) through review of Paul Coverdell National Acute Stroke
Registry Data (5/2002–11/2002) for two of the hospitals.
Four outcomes were studied: survival to hospital discharge,
symptomatic intracerebral haemorrhage (sICH), the presence
of any intracerebral haemorrhage (ICH), and disability at
hospital discharge as determined by modified Rankin score
(mRS) calculated from chart review using previously reported
methodology (18). All ICHs were classified by two indepen-
dent radiologists using the definitions described in the Eur-
opean Cooperative Stroke Study (ECASS) (19). Symptomatic
ICH was defined as parenchymal haemorrhage type 2 as
outlined in ECASS. Disagreements were adjudicated by a third
radiologist. Patients with a prestroke mRS score 41 were
excluded from the outcome analysis of disability. These
patients had preexisting disability and would not be expected
to lose that disability after suffering from a stroke. Poststroke
disability was defined as a mRS of 2 or greater at hospital
discharge. The data were analysed using SPSS software (SPSS
Inc., Chicago, IL).
The associations between outcomes and initial glucose were
determined by logistic regression. Preexisting diagnosis of
diabetes was substituted for glucose in a subsequent analysis
but was not included in the initial model due to the strong
interaction with glucose. Potentially confounding factors of age,
National Institutes of Health Stroke Scale (NIHSS), and smok-
ing within last year were analysed by univariate logistic regres-
sion and those with Po03 were included in a multivariate
model. These variables were prespecified and were chosen for
this analysis as the only pretreatment factors (Po01) from the
NINDS rt-PA trial, which were predictive of symptomatic
haemorrhage (20, 21). The same logistic regression methodol-
ogy as above was also used separately on the patients with and
without preexisting diabetes.
The OR for each adverse outcome per 100 mg/dl increment
in initial glucose was calculated with 95% confidence intervals.
Linear regression was performed between the baseline NIHSS
and the presenting glucose to determine whether an associa-
tion between these variables existed.
Results
Two hundred and seventy-three consecutive tPA-treated acute
stroke patients were studied. Initial blood glucose measure-
ments obtained in the ED were documented for 268 patients;
five patients with unknown glucose were excluded. Only one
patient had documented treatment with insulin in the ED
(initial glucose 206 mg/dl).
Initial glucose ranged from 62 to 507 mg/dl with a mean of
131. In hospital mortality was 128%. Symptomatic ICH
occurred in 66% of cases and any ICH in 99%. Smoking
within the past year, baseline NIHSS, and age were significant
predictors on univariate analyses and were included in all of the
final models examining the relationship between initial glucose
and clinical outcomes. The associations between elevated
glucose at arrival and disability, death, ICH and sICH in tPA-
treated stroke patients were weak and did not reach statistical
significance, though there was a trend towards significance in
the association between glucose and death (Table 1). Trends
were stronger for an association between glucose and death
than with discharge disability, sICH or ICH. When the analysis
was repeated in patients with and without a prior diagnosis of
diabetes, the associations between glucose and the study out-
comes also did not achieve statistical significance. Outcomes
for patients at increasing glucose levels are presented in Figs 1
and 2 (three outlying patients with glucose4300 mg/dl are not
included in these figures). The correlation between baseline
NIHSS and presenting glucose was minimal (adjusted R2
0002). This relationship is plotted in the Appendix.
When diabetes was substituted for glucose in the analysis, a
significant association with the outcomes still was not seen
(Table 2). There was a trend towards a decreased likelihood of
both ICH and sICH, but higher death rates in patients with
diabetes. Tobacco use was not significantly associated with any
of the outcomes.
Discussion
One limitation of this study is the sample size. Although not
statistically significant, some of the OR found in this study are
of magnitudes that conceivably may have achieved significance
with a larger sample. Another limitation is that glucose at
presentation was lower in this cohort than what had been
observed in prior studies of stroke thrombolysis (19, 22).
Hyperglycaemia was less common both in patients with and
without known diabetes compared with other studies, likely
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making adverse effects harder to identify. In addition, trends in
the glucose values over the course of the hospitalisation were
not collected. In addition, we had a relatively small number of
events and this limited the number of covariates that could be
included in the logistic regression model. Last, data on insulin
use outside of the ED were not collected which ideally would be
controlled for since post-tPA control of hyperglycaemia may
affect the post-tPA clinical outcomes and haemorrhage rates.
Two prior studies have specifically examined the relation-
ship between glucose level and stroke outcomes in thrombo-
lytic-treated or eligible patients in the NINDS tPA stroke trial
(1, 20). An analysis of the treatment group alone, in which
glucose was treated as a dichotomous variable (with a cut-off
of 300 mg/dl), showed no statistical difference in outcomes
(20). However, a more recent analysis that included both
treatment and control groups, examined glucose as a contin-
uous variable and concluded that hyperglycaemia on presenta-
tion was associated with significantly lower odds of favourable
outcome and significantly higher odds for sICH, regardless of
tPA treatment (1).
Our study did not confirm a significant association between
hyperglycaemia and outcomes, either because there is no such
association, or because the association is too small to be
detected in this analysis of 268 patients. Hyperglycaemia on
presentation in acute ischaemic stroke patients treated with
tPA was not significantly associated with mortality, disability,
ICH or sICH. Associations too small to be detected with this
sample size cannot be ruled out, however, prior reports have
linked hyperglycaemia to adverse outcomes in similarly sized
or smaller cohorts (8, 21, 23). These data do not disprove the
potential adverse effects of sustained hyperglycaemia. In
addition, these data do not suggest any significant attenuation
of thrombolytic efficacy related to early hyperglycaemia at
presentation within three hours of stroke onset. A larger
analysis of pooled trial data may be more revealing, and may

































Fig. 1 Distribution of initial glucose for subjects with and without sICH
within 36 h of tPA treatment.Distribution of glucose at presentation in study
in mg/dl. Four cases presentedwith glucose4300 mg/dl and none had sICH













Fig. 2 Level of disability at discharge by initial glucose. Distribution of
glucose measurements at presentation measured in mg/dl by level of
disability is depicted. One patient with glucose of 312 mg/dl had mRS of 2,
one patient with glucose of 325 mg/dl had mRS of 4. Two patients died in
the hospital with glucoses of 323 and 507 mg/dl. mRS, modified Rankin
Scale.
Table 1 Relationship of increasing glucose to outcomes by multivariate





in glucose 95% CI P
Death 171 092–313 008
Disability 200 078–509 015
sICH 116 043–313 070
Any ICH 119 053–268 068
OR, odds ratio; CI, confidence interval; sICH, symptomatic intracer-
ebral haemorrhage; ICH, intracerebral haemorrhage.
Table 2 Relationship of diabetes by history to outcomes by multivariate





nondiabetics 95% CI P
Death 199 089–446 0094
Disability 23 0733–7243 0153
sICH 033 0072–150 015
Any ICH 034 00968–12011 0094
OR, odds ratio; CI, confidence interval; sICH, symptomatic intracer-
ebral haemorrhage; ICH, intracerebral haemorrhage.
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lowering therapy trial in acute stroke patients who receive tPA.
Further studies are necessary to better define the relationship
between serum glucose and outcome in tPA-treated acute
ischaemic stroke.
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